Articles

Results from the KEYNOTE-811 clinical trial indicate pembrolizumab added to trastuzumab plus chemotherapy improves response in HER2-positive gastric or gastroesophageal junction cancer. Read More ›

Andecaliximab plus modified (m)FOLFOX6 first-line therapy for metastatic gastric adenocarcinoma did not improve study outcomes in an unselected study population, but improved efficacy was reported in patients ≥65 years of age. Read More ›

Results from a single-arm phase 2 study show ramucirumab plus irinotecan yields promising antitumor activity and safety results in patients with advanced gastric cancer. Read More ›

The addition of neoadjuvant chemotherapy to D2 surgery plus adjuvant chemotherapy improves progression-free survival in patients with resectable locally advanced gastric cancer. Read More ›

Clinical study results indicate pembrolizumab monotherapy improves response rate in patients with advanced refractory esophageal cancer. Read More ›

Avelumab maintenance therapy conveys no overall survival difference over the use of continued chemotherapy in patients with advanced GEJC or gastric cancer. Read More ›

The dose-escalation phase of the EMERGE clinical trial results show that 200 mg domatinostat twice daily is safe and efficacious. Read More ›

No survival advantage was observed with durvalumab use in the PLATFORM clinical trial, but a patient subgroup was observed to have a radiological response. Read More ›

CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer. Read More ›

Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer. Read More ›